Long-term therapeutic plasma exchange in the outpatient setting using an implantable central venous access device

2004 ◽  
Vol 19 (4) ◽  
pp. 180-184 ◽  
Author(s):  
Anneliese Gonzalez ◽  
Donata Sodano ◽  
Janice Flanagan ◽  
Cindy Ouillette ◽  
Robert Weinstein
Keyword(s):  
Plasma Exchange ◽  
Central Venous Access ◽  
Venous Access ◽  
Outpatient Setting ◽  
Therapeutic Plasma Exchange ◽  
Central Venous ◽  
Central Venous Access Device ◽  
Access Device ◽  
Venous Access Device

Implantable central venous access device in infants: Long-term results

2016 ◽  
Vol 58 (10) ◽  
pp. 1027-1031
Author(s):  
Koichi Ohno ◽  
Tatsuo Nakaoka ◽  
Yuichi Takama ◽  
Atsushi Higashio ◽  
Kenji Santo ◽  
...  
Keyword(s):  
Central Venous Access ◽  
Venous Access ◽  
Long Term Results ◽  
Central Venous ◽  
Central Venous Access Device ◽  
Access Device ◽  
Venous Access Device

A new peripherally implanted subcutaneous permanent central venous access device for patients requiring chemotherapy.

1993 ◽  
Vol 11 (11) ◽  
pp. 2181-2185 ◽  
Author(s):  
R R Salem ◽  
B A Ward ◽  
T S Ravikumar
Keyword(s):  
Nursing Staff ◽  
Tracking System ◽  
Central Venous Access ◽  
Venous Access ◽  
Central Venous ◽  
Central Venous Access Device ◽  
Access Device ◽  
Catheter Tip ◽  
Venous Access Device

PURPOSE A peripherally implanted central venous access device (P.A.S. Port; Pharmacia Deltec Inc, St Paul, MN) was evaluated for ease of insertion, functionality, acceptance, and complications in patients who required long-term venous access. A hand-held tracking system (Cath-Finder; Pharmacia Deltec Inc) used to determine catheter tip location was also evaluated. PATIENTS AND METHODS A P.A.S. Port was placed in 47 patients who required long-term intravenous access. The median follow-up duration has been 32 weeks (range, 2 to 112). Total usage has been 2,028 catheter-weeks. The Cath-Finder was used to determine catheter tip location during insertion. Nursing staff and patient satisfaction were polled and functionality and complications were recorded. RESULTS The device was found to be simple to insert, the procedure well tolerated, and, with one exception, the Cath-Finder accurately predicted catheter tip location. There was a 6.4% incidence of transient phlebitis and a 6.4% incidence of symptomatic axillary or subclavian vein thrombosis. There were no infectious complications. Access was simple in all but two obese patients. The device functioned well in all patients, except three in whom blood aspiration was difficult and two in whom fluid administration was slow. The device was well tolerated by all patients and nursing staff satisfaction was high. CONCLUSION This device provides a highly acceptable, additional method of implantable, permanent central venous access for chemotherapy patients with a low complication rate. The successful use of the Cath-Finder and minor extent of the procedure may allow this device to be inserted in a clinic procedure room without sedation and fluoroscopy.

scholarly journals Percutaneous revision of excess length from an implanted long-term central venous access device.

1997 ◽  
Vol 169 (6) ◽  
pp. 1732-1734 ◽  
Author(s):  
J A Kaufman ◽  
C M Fan ◽  
S C Geller ◽  
M J Rieumont ◽  
A C Waltman
Keyword(s):  
Central Venous Access ◽  
Venous Access ◽  
Central Venous ◽  
Central Venous Access Device ◽  
Access Device ◽  
Venous Access Device

Risk factors determining central venous access device-associated deep vein thrombosis resolution in children: a retrospective study

2021 ◽  
Author(s):  
Miguel García-Boyano ◽  
José Manuel Caballero-Caballero ◽  
Marta García Fernández de Villalta ◽  
Mar Gutiérrez Alvariño ◽  
María Jesús Blanco Bañares ◽  
...  
Keyword(s):  
Risk Factors ◽  
Deep Vein Thrombosis ◽  
Central Venous Access ◽  
Venous Access ◽  
Central Venous ◽  
Central Venous Access Device ◽  
Access Device ◽  
Vein Thrombosis ◽  
Venous Access Device ◽  
Deep Vein

scholarly journals How I treat central venous access device–related upper extremity deep vein thrombosis

Blood ◽  
2017 ◽  
Vol 129 (20) ◽  
pp. 2727-2736 ◽  
Author(s):  
Anita Rajasekhar ◽  
Michael B. Streiff
Keyword(s):  
Central Venous Access ◽  
Vena Cava ◽  
Venous Access ◽  
Postthrombotic Syndrome ◽  
Central Venous ◽  
Central Venous Access Device ◽  
Access Device ◽  
Persistent Symptoms ◽  
Vena Cava Filters ◽  
Venous Access Device

AbstractCentral venous access device (CVAD)-related thrombosis (CRT) is a common complication among patients requiring central venous access as part of their medical care. Complications of CRT include pulmonary embolism, recurrent deep venous thrombosis, loss of central venous access, and postthrombotic syndrome. Patient-, device-, and treatment-related factors can influence the risk of CRT. Despite numerous randomized controlled trials, the clinical benefit of pharmacologic thromboprophylaxis for the prevention of CRT remains to be established. Therefore, minimizing patient exposure to known risk factors is the best available approach to prevent CRT. Venous duplex is recommended for the diagnosis of CRT. Anticoagulation for at least 3 months or the duration of the indwelling CVAD is recommended for treatment of CRT. Thrombolysis should be considered for patients at low risk for bleeding who have limb-threatening thrombosis or whose symptoms fail to resolve with adequate anticoagulation. CVAD removal should be consider for patients with bacteremia, persistent symptoms despite anticoagulation, and if the CVAD is no longer needed. Superior vena cava filters should be avoided. Prospective studies are needed to define the optimal management of patients with or at risk for CRT.

Sign in / Sign up

Export Citation Format

Share Document